These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 9234794

  • 1. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.
    Nardelli-Haefliger D, Roden RB, Benyacoub J, Sahli R, Kraehenbuhl JP, Schiller JT, Lachat P, Potts A, De Grandi P.
    Infect Immun; 1997 Aug; 65(8):3328-36. PubMed ID: 9234794
    [Abstract] [Full Text] [Related]

  • 2. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
    Revaz V, Benyacoub J, Kast WM, Schiller JT, De Grandi P, Nardelli-Haefliger D.
    Virology; 2001 Jan 05; 279(1):354-60. PubMed ID: 11145916
    [Abstract] [Full Text] [Related]

  • 3. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1.
    Baud D, Ponci F, Bobst M, De Grandi P, Nardelli-Haefliger D.
    J Virol; 2004 Dec 05; 78(23):12901-9. PubMed ID: 15542642
    [Abstract] [Full Text] [Related]

  • 4. The nature of the attenuation of Salmonella typhimurium strains expressing human papillomavirus type 16 virus-like particles determines the systemic and mucosal antibody responses in nasally immunized mice.
    Benyacoub J, Hopkins S, Potts A, Kelly S, Kraehenbuhl JP, Curtiss R, De Grandi P, Nardelli-Haefliger D.
    Infect Immun; 1999 Jul 05; 67(7):3674-9. PubMed ID: 10377159
    [Abstract] [Full Text] [Related]

  • 5. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.
    Park JS, Oh YK, Kang MJ, Kim CK.
    J Med Virol; 2003 Aug 05; 70(4):633-41. PubMed ID: 12794729
    [Abstract] [Full Text] [Related]

  • 6. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
    Fraillery D, Baud D, Pang SY, Schiller J, Bobst M, Zosso N, Ponci F, Nardelli-Haefliger D.
    Clin Vaccine Immunol; 2007 Oct 05; 14(10):1285-95. PubMed ID: 17687110
    [Abstract] [Full Text] [Related]

  • 7. Papillomavirus-like particles for serology and vaccine development.
    Kirnbauer R.
    Intervirology; 1996 Oct 05; 39(1-2):54-61. PubMed ID: 8957670
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast.
    Lowe RS, Brown DR, Bryan JT, Cook JC, George HA, Hofmann KJ, Hurni WM, Joyce JG, Lehman ED, Markus HZ, Neeper MP, Schultz LD, Shaw AR, Jansen KU.
    J Infect Dis; 1997 Nov 05; 176(5):1141-5. PubMed ID: 9359711
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model.
    Yan X, Wang D, Liang F, Fu L, Guo C.
    Hum Vaccin Immunother; 2014 Nov 05; 10(12):3491-8. PubMed ID: 25483698
    [Abstract] [Full Text] [Related]

  • 16. Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant.
    Oh YK, Sohn T, Park JS, Kang MJ, Choi HG, Kim JA, Kim WK, Ko JJ, Kim CK.
    Virology; 2004 Oct 25; 328(2):266-73. PubMed ID: 15464846
    [Abstract] [Full Text] [Related]

  • 17. Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice.
    Nardelli-Haefliger D, Roden R, Balmelli C, Potts A, Schiller J, De Grandi P.
    J Virol; 1999 Nov 25; 73(11):9609-13. PubMed ID: 10516071
    [Abstract] [Full Text] [Related]

  • 18. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
    Jagu S, Karanam B, Wang JW, Zayed H, Weghofer M, Brendle SA, Balogh KK, Tossi KP, Roden RBS, Christensen ND.
    Vaccine; 2015 Oct 13; 33(42):5553-5563. PubMed ID: 26382603
    [Abstract] [Full Text] [Related]

  • 19. Synthesis, properties and applications of papillomavirus-like particles.
    Sapp M, Volpers C, Streeck RE.
    Intervirology; 1996 Oct 13; 39(1-2):49-53. PubMed ID: 8957669
    [Abstract] [Full Text] [Related]

  • 20. Aerosol delivery of virus-like particles to the genital tract induces local and systemic antibody responses.
    Hunter Z, Tumban E, Dziduszko A, Chackerian B.
    Vaccine; 2011 Jun 20; 29(28):4584-92. PubMed ID: 21549786
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.